Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, was featured in a recent episode of the BioMedWire Podcast. During the program, Executive Co-Chairman and Co-Founder Anthony Durkacz discussed the company’s strategy for advancing Lucid-MS, its lead drug candidate for multiple sclerosis, as well as the commercial opportunity surrounding its unbuzzd product. Durkacz highlighted Lucid-MS’s goal of addressing mobility damage associated with MS and noted that the company has filed an investigational new drug application for a Phase 2 clinical trial, which could represent the candidate’s first administration to human MS patients. He also discussed unbuzzd, a commercially available product designed to accelerate alcohol metabolism, underscoring Quantum BioPharma’s strategy of combining clinical-stage pharmaceutical development with commercial opportunities across neurodegenerative, metabolic and alcohol-misuse conditions.
To view the full article, visit https://nnw.fm/Z1YUI
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer